Gastrointestinal events after opioid treatment in nonmalignant pain: Correlates of occurrence and impact on health-related quality of life

Authors

  • Kate L. Lapane, PhD University of Massachusetts Medical School Quantitative Health Sciences 55 Lake Avenue North Worcester, MA 01655 508-856-8965 508-856-8993 (fax)
  • Brian J. Quilliam, PhD University of Rhode Island Pharmacy Practice 40 Lower College Road Kingston, Rhode Island 02881 4018742030 4018742181 (fax)
  • Carmela Benson, MS Ortho McNeil Janssen Scientific Affairs, LLC 1000 Route 202 Raritan, NJ 08869 (908) 927-5102 (908) 218-1286 (fax)
  • Wing Chow, PharmD, MPH Janssen Scientific Affairs, LLC Health Economics and Outcomes Research 1000 Route 202 Room 3255 Raritan, New Jersey 08869 908/927-5102 908/218-1286 (fax)
  • Myoung S. Kim, PhD, MBA Ortho McNeil Janssen Scientific Affairs, LLC 1000 Route 202 Room 3204 Raritan, NJ 08869 (908) 218-6419 (908) 218-1286 (fax)

DOI:

https://doi.org/10.5055/jom.2013.0161

Abstract

Background: Gastrointestinal (GI) adverse effects are common with oral opioid treatments; their impact on health-related quality of life (HRQoL) is poorly understood.

Objectives: To estimate the extent to which GI adverse effects impact HRQoL.

Design: 28-day prospective, multicenter, observational registry.

Setting: Outpatient settings.

Participants: Six hundred thirty-nine patients with acute pain (AP; n = 243) and acute episodes of chronic pain (CP; pain 3 months; n = 396) requiring treatment with a prescription medication containing oxycodone immediaterelease on an as-needed basis for 5 days.

Measurements: Modified Memorial Symptom Assessment Scale; 12-item Short Form Health Survey (SF-12) Physical (PCS); and Mental Component Scales (MCS) on days 3, 7, 14, 21, and 28. Repeated measures mixed models provided estimates

of impact of GI events on HRQoL.

Results: Forty-seven percent of AP patients and 24 percent of CP patients developed constipation. More AP patients than CP developed nausea (31 percent vs 19 percent). After adjustment for confounders, constipation was associated with a 3.9-point reduction in PCS and a 2.3-point reduction in MCS among AP patients (p < 0.0001). Among AP patients, nausea/vomiting was associated with a reduction in PCS (PCS = 3.2; p < 0.0001) and MCS (MCS = 2.2; p = 0.0042). Among CP patients, constipation was not associated with reductions in HRQoL, and nausea/ vomiting was associated with a reduction in MCS but not PCS (MCS = 2.4; p 0.0001).

Conclusion: GI symptoms accompanying oral opioid treatment are common and negatively affect HRQoL differentially for those with AP and CP. Effective approaches for managing opioid-induced GI symptoms are warranted.

Keywords: pain, gastrointestinal adverse events, ambulatory care, opioids, registry

DOI:10.5055/jom.2013.0161

References

National Center for Health Statistics: Health, United States, 2006. Hyattsville, MD: National Center for Health Statistics, 2006.

Sawyer P, Bodner EV, Ritchie CS, et al.: Pain and pain medication use in community-dwelling older adults. Am J Geriatr Pharmacotherapy. 2006; 4: 316-324.

Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012; 13(8): 715-724.

The Joint Commission: Facts about pain management, 2011. Available at http://www.jointcommission.org/pain_management/. Accessed 12 March, 2011.

Lippe PM: The decade of pain control and research. Pain Med. 2000;1:286.

S. 2607–106th Congress. Pain Relief Promotion Act of 2000, 2000.

Moskovits BL, Benson CJ, Patel AA, et al.: Analgesic treatment for moderate to severe acute pain in the US: Patients’ perspectives in the Physicians Partnering Again Pain (P3) Survey. J Opioid Manag. 2011; 7: 277-286.

Apfelbaum JL, Chen C, Mehta SS, et al.: Postoperative pain experience: Results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003; 97: 534-540.

Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10: 113-1301.

American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons: Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009; 57: 1331-1346.

Noble M, Tregear SJ, Treadwell JR, et al.: Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008; 35(2): 214-228.

Kalso E, Edwards JA, Moore RA, et al.: Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 2004; 112: 372-380.

Werawatganon T, Charuluxanun S: Patient controlled intravenous opioid analgesia versus continuous epidural analgesia for pain after intra-abdominal surgery. Cochrane Database Syst Rev. 2005; (1): CD004088.

Kim M, Benson C, Chow W, et al.: Design of the Oxycodone Users Registry (OUR): A prospective, multicenter registry of patients with non-malignant pain. J Opioid Manag. 2013; 9: 189-204.

Kim M, Benson C, Chow W, et al.: Design of the Oxycodone Users Registry (OUR): A prospective, multicenter registry of patients with non-malignant pain. J Pain. 2010; 11(4)Suppl 1: S49 [abstract 293].

IOM (Institute of Medicine): Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press, 2011.

Portenoy RK, Thaler HT, Kornblith AB, et al.: The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994; 30A: 1326-1336.

Apelbaum JL, Gan TJ, Zhao S, et al.: Reliability and validity of the perioperative opioid-related symptom distress scale. Anesth Analg. 2004; 99: 699-709.

Shalev V, Chodick G, Heymann AD, et al.: Gender differences in healthcare utilization and medical indicators among patients with diabetes. Public Health. 2005; 119: 45-49.

Bertakis KD, Azari R, Helms LJ, et al.: Gender differences in the utilization of health care services. J Fam Pract. 2000; 49: 147-152.

Owens GM: Gender differences in health care expenditures, resource utilization, and quality of care. J Managed Care Pharm. 2008; 14: 2-6.

Field TS, Gurwitz JH, Harrold LR, et al.: Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004; 52: 1349-1354.

Mitchell SJ, Hilmer SN, McLachlan AJ: Clinical pharmacology of analgesics in old age and frailty. Rev Clin Gerontol. 2009; 19: 103-118.

Dorr DA, Jones SS, Burns L, et al.: Use of health-related, quality-of-life metrics to predict mortality and hospitalizations in community-dwelling seniors. J Am Geriatr Soc. 2006; 54(4): 667-673.

Singh JA, Nelson DB, Fink HA, et al.: Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physiciandiagnosed arthritis: The veterans arthritis quality of life study. Semin Arthritis Rheum. 2005; 34(5): 755-765.

Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34: 220-233.

Ware JE Jr, Kosinski M, Turner-Bowker D, et al.: User’s Manual for the SF-12v2™ Health Survey with a Supplement Documenting SF-12.5 R_Health Survey. Lincoln, RI: QualityMetric Incorporated, 2002.

Kutner MH, Nachtsheim CJ, Neter J, et al.: Applied Linear Statistical Models, 5th ed. New York, NY: McGraw-Hill Irwin, 2005.

Iyer S, Davis KL, Candrilli S: Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010; 19(3): 44-51.

Kwong JW, Diels J, Kavanagh S: Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010; 44: 630-640.

Cook SF, Lanza L, Zhou X, et al.: Gastrointestinal adverse effects in chronic opioid users: Results from a population-based survey. Aliment Pharmacol Ther. 2008; 27: 1224-1232.

Bliven BD, Kaufman SE, Spertus JA: Electronic collection of health-related quality of life data: Validity, time benefits, and patient preference. Qual Life Res. 2001; 10(1): 15-22.

Bell T, Annunziata K, Leslie JB: Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: Findings from the National Health and Wellness Survey. J Opioid Manag. 2009; 5(3): 137-144.

Annemans L: Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. Clin Drug Investig. 2011; 31(2): 73-86.

Anastassopoulos KP, Chow W, Ackerman SJ, et al.: Oxycodone-related side effects: Impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. J Opioid Manag. 2011; 7: 203-215.

Published

05/01/2013

How to Cite

Lapane, PhD, K. L., B. J. Quilliam, PhD, C. Benson, MS, W. Chow, PharmD, MPH, and M. S. Kim, PhD, MBA. “Gastrointestinal Events After Opioid Treatment in Nonmalignant Pain: Correlates of Occurrence and Impact on Health-Related Quality of Life”. Journal of Opioid Management, vol. 9, no. 3, May 2013, p. 205—216, doi:10.5055/jom.2013.0161.

Issue

Section

Articles